Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.

We identified two selective HDAC inhibitors that blocked proliferation of glioblastoma cells, but did not affect astrocyte survival. These new and highly effective inhibitors should be considered as promising candidates for further investigation in preclinical GBM models.